文献速递慢阻肺肺结节与肺癌

国家肺癌筛查试验中气流受限与筛查期间死亡率的关系:为何量化气流受限很重要

Airflow limitation and mortality during cancer screening in the National Lung Screening Trial: why quantifying airflow limitation matters.
PubMed 文献 · Thorax · 2022-12-01

结果显示气流受限越重,肺癌发生和死亡风险越高,但重度气流受限(GOLD 3-4级)者筛查未见肺癌死亡率下降,且非肺癌死亡风险更高。

要点

  • 气流受限越重,肺癌发病和死亡风险越高。
  • 重度气流受限者筛查未显示肺癌死亡率下降。
  • 无气流受限者CT筛查较胸片显著降低肺癌死亡。

核心结论

  • 尽管重度气流受限者肺癌风险更高,但筛查未带来明显的肺癌死亡率下降。

主要发现

  • 随着气流受限加重,肺癌发生风险增加(效应量=0.34,p<0.0001),肺癌死亡风险也增加(效应量=0.35,p<0.0001)。
  • 重度气流受限(GOLD 3-4级)者肺癌风险和肺癌死亡率最高,但腺癌更少(效应量=-0.20,p=0.008),手术率更低(效应量=-0.16,p=0.014),且非肺癌死亡相对肺癌死亡的效应量为0.30(p<0.0001)。
  • 无气流受限者中,CT筛查较胸片显著降低肺癌死亡(30.3%,95%CI 4.5%至49.2%,p<0.05)。
  • 有气流受限者中,肺癌死亡降低幅度为18.5%(95%CI -8.4%至38.7%,p>0.05),未达统计学显著性,可能归因于GOLD 3-4级者未见明显死亡率下降。

关键数值与推荐

  • 肺癌发生风险随气流受限加重而增加(效应量=0.34,p<0.0001)。
  • 肺癌死亡风险随气流受限加重而增加(效应量=0.35,p<0.0001)。
  • 无气流受限者CT筛查较胸片降低肺癌死亡30.3%(95%CI 4.5%至49.2%,p<0.05)。
  • 有气流受限者肺癌死亡降低18.5%(95%CI -8.4%至38.7%,p>0.05)。

临床怎么用

  • 筛查获益因气流受限程度而异,需量化气流受限以评估个体获益。
  • 重度气流受限者筛查获益不明显,应综合评估合并症和竞争风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Current eligibility criteria for lung cancer (LC) screening are derived from randomised controlled trials and primarily based on age and smoking history. However, the individual benefits of screening are highly variable and potentially attenuated by co-morbidities such as advanced airflow limitation (AL). OBJECTIVE: To examine the relationship between the presence and severity of AL and screening outcomes. METHODS: This was a secondary analysis of 18 463 high-risk smokers, a substudy from the National Lung Screening Trial, who underwent pre-bronchodilator spirometry at baseline and median follow-up of 6.1 years. We used descriptive statistics and a competing risk proportional hazards model to examine differences in screening outcomes by chronic obstructive pulmonary disease severity group. RESULTS: The risk of developing LC increased with worsening AL (effect size=0.34, p<0.0001), as did the risk of dying of LC (effect size=0.35, p<0.0001). While those with severe AL (Global Initiative for Obstructive Lung Disease, GOLD grade 3-4) had the highest risk of LC and the highest LC mortality, they also had fewer adenocarcinomas (effect size=-0.20, p=0.008) and a lower surgery rate (effect size=-0.16, p=0.014) despite comparable staging, and greater non-LC mortality relative to LC mortality (effect size=0.30, p<0.0001). In participants with no AL, screening with CT was associated with a significant reduction in LC deaths relative to chest X-ray (30.3%, 95% CI 4.5% to 49.2%, p<0.05). The clinically relevant but attenuated reduction in those with AL (18.5%, 95% CI -8.4% to 38.7%, p>0.05) could be attributed to GOLD 3-4, where no appreciable mortality reduction was observed. CONCLUSION: Despite a greater risk of LC, severe AL was not associated with any apparent reduction in LC mortality following screening.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Young RP, Ward RC, Scott RJ, et al. Airflow limitation and mortality during cancer screening in the National Lung Screening Trial: why quantifying airflow limitation matters. Thorax. 2022. PMID: 36456179. doi:10.1136/thorax-2022-219334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。